Navigation Links
BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
Date:1/19/2011

NOVATO, Calif., Jan. 19, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has initiated a Phase 1/2 trial for BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA) in development for the treatment of Pompe disease.

"We have a strong track record of quickly developing enzyme replacement therapies for unmet medical needs and expect to leverage our clinical and regulatory experience and manufacturing know-how in the development of BMN 701," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin.  "There is a significant amount of interest in the medical community for a more effective treatment option for late-onset Pompe disease, and we believe, based on in vitro and in vivo nonclinical studies, that using our proprietary Glycosylation Independent Lysosomal Targeting, or GILT technology, BMN 701 has the potential to deliver more enzyme to lysosomes compared to traditional mannose-6-phosphate targeted approaches."  

The Phase 1/2 trial is an open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and clinical activity of BMN 701 administered as an intravenous infusion every two weeks at doses of 5 mg/kg, 10 mg/kg and 20 mg/kg.  The company expects to enroll approximately 30 patients between the ages of 13 and 65 years old with late-onset Pompe disease for a treatment period of 24 weeks.

About Pompe DiseasePompe disease, a lysosomal storage disorder, is a progressive degenerative disease of skeletal muscle including respiratory muscles such as diaphragm, and of heart muscle in infant-onset patients.  It is caused by a deficiency in the lysosomal enzyme acid alpha glucosidase which leads to the accumulation of glycogen in muscle cell lysosomes and results in cell death.  The incidence is one in 40,000 births. 
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
(Date:1/14/2014)... 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio ... acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... of the acquisition were not disclosed. Progressive ... a wide range of sleep, mobility, and respiratory products to ...
(Date:1/14/2014)... 14, 2014   NuAire , a manufacturer of ergonomically designed ... Hitachi Koki of Japan to sell ... America . NuAire will utilize its network of sales professionals ... Canada to offer assistance in application use, product benefits ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... (OMX Nordic: ACTI) presented,pre-clinical results for the ... League Against Rheumatism, <a target="_blank" href=,"http://www.eular.org/">www.eular.org ... data presented show that I-3D has a,significant ... model for rheumatoid arthritis (RA)", commented Sven,Andréasson, ...
... /PRNewswire/ -- Solstice,Neurosciences, Inc. today reported important results ... Toxin Type B,Injectable Solution (Myobloc(R)) recently presented at ... in,Istanbul, Turkey. , This was the first multicenter ... treatment doses of 10,000 Units, 12,500,Units, and 15,000 ...
Cached Medicine Technology:New Positive Pre-clinical Data for Active Biotech's RA Project I-3D 2Solstice Neurosciences Presents Escalating Dose Study at,International Congress in Istanbul, Turkey 2Solstice Neurosciences Presents Escalating Dose Study at,International Congress in Istanbul, Turkey 3Solstice Neurosciences Presents Escalating Dose Study at,International Congress in Istanbul, Turkey 4
(Date:7/10/2014)... more likely to be diagnosed with more aggressive ... for shorter times than prostate cancer patients who ... , The negative outcomes may be the result ... mentally ill, depression,s impact on biological cancer processes, ... general health and disinterest in receiving more effective ...
(Date:7/10/2014)... Men who experience hot flashes are unlikely to talk ... their silent suffering if they are willing to ... Baylor University case study., After seven weeks of hypnotic ... flashes following prostate cancer surgery showed a drastic decrease ... improvement in sleep quality, according to the study., The ...
(Date:7/9/2014)... first time, researchers have access to detailed information about ... care. A new study, called Our Health Counts, uses ... faced by urban Aboriginal people in Canada according ... findings, published today in BMJ Open , illustrate ... general population. , Researchers interviewed 554 First Nations adults ...
(Date:7/9/2014)... all types of cancer sends the protein factories in ... tumour,s uncontrolled growth, new research suggests. , Scientists at ... trigger responsible for ratcheting up activity of the endoplasmic ... building blocks cancer cells need to keep growing. , ... controls the flow of messages to the endoplasmic reticulum ...
(Date:7/9/2014)... Cancer Center paint a relatively optimistic picture of women,s ... have spread to the chest wall or skin, but ... skin, regardless of size and whether they have involved ... and called "locally advanced" tumors, suggesting that they are ... survival. Locally advanced breast cancers of this and other ...
Breaking Medicine News(10 mins):Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Urban Aboriginal people face unique health challenges 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3
... pulmonary disorder is widespread but can be prevented , FRIDAY, ... for the diagnosis, management and prevention of a widespread, deadly ... affects 15 percent to 25 percent of adults over the ... death in the United States. It,s expected to become the ...
... Sept. 14 Aid provided by,The Prem Rawat Foundation ... women and their families who were victims of the ... After the flooding, caused by cyclones in this area ... displaced from their homes. The,Prem Rawat Foundation made a ...
... NNN Healthcare/Office REIT,Inc. has acquired 2750 Monroe ... September 10, 2007. 2750 Monroe Boulevard is ... feet, as well as an accessory building used,for ... on a 10.5-acre parcel,in the Valley Forge Corporate ...
... Va., Sept. 14 AMERIGROUP,Corporation (NYSE: AGP ) ... The event will be held at the Grand Hyatt ... presentations with the AMERIGROUP management team,beginning at 8:30 a.m. ... Frieden, who is Convener of,AMERIGROUP,s National Advisory Board on ...
... Company,(Nasdaq: PRGO ; TASE) today announced that President ... will provide a review of the Company,business for the ... a.m. EST in New York. The meeting will ... http://www.perrigo.com or by phone at 866-383-5538, participant,code ...
... fewer serious birth defects, U.S. experts say , , FRIDAY, Sept. ... increased among American women since the federal government mandated folate ... how much folate is enough -- or too much. , ... and Prevention (CDC) finds that the number of women of ...
Cached Medicine News:Health News:Experts Publish New Lung Disease Guidelines 2Health News:The Prem Rawat Foundation Supports Disaster-Relief Efforts in Mozambique 2Health News:NNN Healthcare/Office REIT Acquires 2750 Monroe Boulevard in Valley Forge, Pennsylvania 2Health News:NNN Healthcare/Office REIT Acquires 2750 Monroe Boulevard in Valley Forge, Pennsylvania 3Health News:AMERIGROUP Corporation to Host Investor Day 2Health News:Perrigo Company to Host Analyst Meeting on September 18, 2007 2Health News:Women's Folic Acid Levels Improving 2Health News:Women's Folic Acid Levels Improving 3Health News:Women's Folic Acid Levels Improving 4
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Steroid eluting pacemaker leads...
... Medtronic presents the Streamline family of temporary ... taken the gold standard in temporary pacing ... make them easy to use and less ... 6491 Unipolar Pediatric Temporary Pacing Lead is ...
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Medicine Products: